UNLABELLED: Deoxycytidine kinase (dCK) is a rate-limiting enzyme in the deoxyribonucleoside salvage pathway and a critical determinant of therapeutic activity for several nucleoside analog prodrugs. We have previously reported the development of 1-(2'-deoxy-2'-(18)F-fluoro-beta-D-arabinofuranosyl)cytosine ((18)F-FAC), a new probe for PET of dCK activity in immune disorders and certain cancers. The objective of the current study was to develop PET probes with improved metabolic stability and specificity for dCK. Toward this goal, several candidate PET probes were synthesized and evaluated in vitro and in vivo. METHODS: High-pressure liquid chromatography was used to analyze the metabolic stability of (18)F-FAC and several newly synthesized analogs with the natural D-enantiomeric sugar configuration or the corresponding unnatural L-configuration. In vitro kinase and uptake assays were used to determine the affinity of the (18)F-FAC L-nucleoside analogs for dCK. The biodistribution of selected L-analogs in mice was determined by small-animal PET/CT. RESULTS: Candidate PET probes were selected using the following criteria: low susceptibility to deamination, high affinity for purified recombinant dCK, high uptake in dCK-expressing cell lines, and biodistribution in mice reflective of the tissue-expression pattern of dCK. Among the 10 newly developed candidate probes, 1-(2'-deoxy-2'-(18)F-fluoro-beta-L-arabinofuranosyl)cytosine (L-(18)F-FAC) and 1-(2'-deoxy-2'-(18)F-fluoro-beta-L-arabinofuranosyl)-5-methylcytosine (L-(18)F-FMAC) most closely matched the selection criteria. The selection of L-(18)F-FAC and L-(18)F-FMAC was validated by showing that these two PET probes could be used to image animal models of leukemia and autoimmunity. CONCLUSION: Promising in vitro and in vivo data warrant biodistribution and dosimetry studies of L-(18)F-FAC and L-(18)F-FMAC in humans.
UNLABELLED: Deoxycytidine kinase (dCK) is a rate-limiting enzyme in the deoxyribonucleoside salvage pathway and a critical determinant of therapeutic activity for several nucleoside analog prodrugs. We have previously reported the development of 1-(2'-deoxy-2'-(18)F-fluoro-beta-D-arabinofuranosyl)cytosine ((18)F-FAC), a new probe for PET of dCK activity in immune disorders and certain cancers. The objective of the current study was to develop PET probes with improved metabolic stability and specificity for dCK. Toward this goal, several candidate PET probes were synthesized and evaluated in vitro and in vivo. METHODS: High-pressure liquid chromatography was used to analyze the metabolic stability of (18)F-FAC and several newly synthesized analogs with the natural D-enantiomeric sugar configuration or the corresponding unnatural L-configuration. In vitro kinase and uptake assays were used to determine the affinity of the (18)F-FAC L-nucleoside analogs for dCK. The biodistribution of selected L-analogs in mice was determined by small-animal PET/CT. RESULTS: Candidate PET probes were selected using the following criteria: low susceptibility to deamination, high affinity for purified recombinant dCK, high uptake in dCK-expressing cell lines, and biodistribution in mice reflective of the tissue-expression pattern of dCK. Among the 10 newly developed candidate probes, 1-(2'-deoxy-2'-(18)F-fluoro-beta-L-arabinofuranosyl)cytosine (L-(18)F-FAC) and 1-(2'-deoxy-2'-(18)F-fluoro-beta-L-arabinofuranosyl)-5-methylcytosine (L-(18)F-FMAC) most closely matched the selection criteria. The selection of L-(18)F-FAC and L-(18)F-FMAC was validated by showing that these two PET probes could be used to image animal models of leukemia and autoimmunity. CONCLUSION: Promising in vitro and in vivo data warrant biodistribution and dosimetry studies of L-(18)F-FAC and L-(18)F-FMAC in humans.
Authors: K Lotfi; E Månsson; T Spasokoukotskaja; B Pettersson; J Liliemark; C Peterson; S Eriksson; F Albertioni Journal: Clin Cancer Res Date: 1999-09 Impact factor: 12.531
Authors: Gerald Toy; Wayne R Austin; Hsiang-I Liao; Donghui Cheng; Arun Singh; Dean O Campbell; Tomo-o Ishikawa; Lynn W Lehmann; Nagichettiar Satyamurthy; Michael E Phelps; Harvey R Herschman; Johannes Czernin; Owen N Witte; Caius G Radu Journal: Proc Natl Acad Sci U S A Date: 2009-12-31 Impact factor: 11.205
Authors: Rachel E Laing; Martin A Walter; Dean O Campbell; Harvey R Herschman; Nagichettiar Satyamurthy; Michael E Phelps; Johannes Czernin; Owen N Witte; Caius G Radu Journal: Proc Natl Acad Sci U S A Date: 2009-02-05 Impact factor: 11.205
Authors: Dean O Campbell; Shahriar S Yaghoubi; Ying Su; Jason T Lee; Martin S Auerbach; Harvey Herschman; Nagichettiar Satyamurthy; Johannes Czernin; Arnon Lavie; Caius G Radu Journal: J Biol Chem Date: 2011-11-09 Impact factor: 5.157
Authors: Jason T Lee; Dean O Campbell; Nagichettiar Satyamurthy; Johannes Czernin; Caius G Radu Journal: J Nucl Med Date: 2012-02 Impact factor: 10.057
Authors: Jelena Levi; Tina Lam; Samuel R Goth; Shahriar Yaghoubi; Jennifer Bates; Gang Ren; Salma Jivan; Tony L Huynh; Joseph E Blecha; Roli Khattri; Karl F Schmidt; Dominique Jennings; Henry VanBrocklin Journal: Cancer Res Date: 2019-05-07 Impact factor: 12.701
Authors: Jessica R Salas; Bao Ying Chen; Alicia Wong; Donghui Cheng; John S Van Arnam; Owen N Witte; Peter M Clark Journal: J Nucl Med Date: 2018-04-26 Impact factor: 10.057
Authors: James Russell; Nagavarakishore Pillarsetty; Robin M Kramer; Paul B Romesser; Pooja Desai; Adriana Haimovitz-Friedman; Maeve A Lowery; John L Humm Journal: Mol Imaging Biol Date: 2017-12 Impact factor: 3.488
Authors: Henry Herman; Graciela Flores; Kevin Quinn; Mark Eddings; Sebastian Olma; Melissa D Moore; Huijiang Ding; Krzysztof P Bobinski; Mingwei Wang; Dirk Williams; Darin Wiliams; Clifton Kwang-Fu Shen; Michael E Phelps; R Michael van Dam Journal: Appl Radiat Isot Date: 2013-04-25 Impact factor: 1.513